Antimicrobial resistance (AMR) is a major threat to health, which was associated with 5 million deaths globally in 2019 and against which efficient medical countermeasures are lacking. Therefore, promoting access to medicines that could assist in the fight against antimicrobial resistance is essential.
The unavailability of age-appropriate medicines for the treatment of antimicrobial-susceptible paediatric tuberculosis across Europe is a matter of concern. Importantly, sub-optimal first-line treatment of tuberculosis increases the risk of the emergence of AMR.
In this context, HaDEA has launched the call for tenders HADEA/2023/OP/0052 to speed-up the development, availability and access to anti-tuberculosis medicines for children
The subject of this call for tenders is to conclude a service contract for purchasing services to speed up availability and access to age-appropriate anti-tuberculosis medicines in the EU. The selected contractor will carry out clinical and/or non-clinical services for finalising the development and submitting the market authorisation for the concerned products for their commercialisation in the EU.
Budget: € 5 000 000
Find out more and apply on the Funding and Tenders Portal.
All interested parties are invited to send in their applications by 11 April 2024, 15:00 (CEST).
Background
EU4Health, with a budget of €5.3 billion, is the fourth and largest of the EU health programmes. The EU4Health programme goes beyond an ambitious response to the COVID-19 crisis to address the resilience of European healthcare systems. The programme provides funding to national authorities, health organisations and other bodies through grants and public procurement, contributing to a healthier Europe.